- Geneos Therapeutics, Pa.-based clinical stage company, closed its Series A1 round, raising $12m in financing
- The round led by Korea Investment Partners– Global Bio Fund with participation from existing investors Santé Ventures and Inovio Pharmaceuticals, Inc
- In conjunction with the financing, Mr. Sangwoo Lee, Managing Director Korea Investment Partners USA Inc. joined Geneos’ Board of Directors
- Geneos Therapeutics also develops personalized therapies for cancer using its GT-EPIC™ platform to target unique neoantigens from individual patient tumors
- The company’s GT-EPIC Neoantigen-Targeting Platform is based on a clinically-validated DNA medicines technology exclusively licensed from Inovio Pharmaceuticals, Inc
